PolyPeptide Group AG (CH:PPGN)
:PPGN
Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF29.80
CHF1.30(6.77%)
At close: 4:00 PM EST
CHF29.80
CHF1.30(6.77%)
Day’s Range― - ―
52-Week RangeCHF19.86 - CHF43.50
Previous CloseN/A
Volume22.87K
Average Volume (3M)34.07K
Market Cap
CHF1.31B
Enterprise ValueCHF1.37B
Total Cash (Recent Filing)CHF74.53M
Total Debt (Recent Filing)CHF130.46M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 13, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF40.50Price Target Upside35.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.76
Revenue Forecast (FY)CHF487.64M
Bulls Say, Bears Say
Bulls Say
CDMO Recurring Revenue ModelPolyPeptide’s CDMO business combines development fees, clinical and commercial manufacturing revenues. That mix creates recurring commercial supply contracts and project-based development work, increasing customer stickiness and providing durable demand as programs advance to commercial scale.
Consistent Revenue GrowthA steady top-line (+6.2% in 2025) signals expanding commercial traction across customers and projects. Persistent revenue growth supports better capacity utilization, spreads fixed costs, and forms a foundation for structural margin recovery and scalable operating leverage over the coming months.
Improving Operating Cash FlowImproved operating cash flow in 2024–2025 shows core operations generate cash even while accounting profitability lags. Reliable OCF reduces reliance on external financing, funds working capital and selective capex, and underpins multi-month solvency and capacity investments if maintained.
Bears Say
Ongoing Net LossesSustained net losses through 2023–2025 mean the company has yet to convert operating recovery into bottom-line profitability. Continued losses erode equity, limit retained-capital reinvestment, and increase reliance on external funding or dilutive measures absent durable margin improvement.
Volatile Free Cash FlowFree-cash-flow volatility—positive in 2024 then sharply negative in 2025—signals uneven cash left after investment. This raises funding risk for debt servicing and capex, can force short-term financing or cutbacks, and weakens the company’s buffer against operational setbacks.
Rising LeverageMeaningful increases in leverage since 2021–2022 (even from moderate starting D/E) reduce financial flexibility. Higher debt amplifies interest and covenant risks, constrains strategic investments or bolt-on M&A, and magnifies downside if revenue or margin recovery stalls.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF19.86 and its highest was CHF43.50 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.31B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Aug 13, 2026 which is in 48 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Mar 12, 2026. The company reported CHF0.152 earnings per share for the quarter, missing the consensus estimate of CHF0.268 by -CHF0.116.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.06.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.152 in its last earnings report, missing expectations of CHF0.268. Following the earnings report the stock price went up 8.776%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF40.50
▲(35.91% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―
Options Prices
Currently, No data available
---